Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 103.14B +0.9% |
| Revenue (ttm) | 23.66B +19.2% |
| Net Income | 6.13B -15.0% |
| EPS | 97.77 -12.3% |
| Shares Out | 61.39M |
| PE Ratio | 17.18 |
| Forward PE | 21.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,141 |
| Average Volume | 145,464 |
| Open | 1,667.50 |
| Previous Close | 1,680.00 |
| Day's Range | 1,645.00 - 1,681.00 |
| 52-Week Range | 1,157.00 - 2,257.00 |
| Beta | 0.75 |
| RSI | 31.56 |
| Earnings Date | May 7, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n... [Read more]
Financial Performance
In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.
Financial numbers in USD Financial StatementsNews
Passing of Genmab A/S' Annual General Meeting
Company Announcement At Genmab A/S' Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approved Discharge was given to the Board of Directors and the Executive Management...
Completion of Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; March 16, 2026 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 13, 2026. On February 17, 2026, Genmab announ...
Genmab A/S at Barclays Global Healthcare Conference Transcript
Genmab A/S at Barclays Global Healthcare Conference Transcript
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Harbor Health Care ETF Q4 2025 Portfolio Review
Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly deliv...
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 share...
Genmab A/S at TD Cowen Healthcare Conference Transcript
Genmab A/S at TD Cowen Healthcare Conference Transcript
Correction to Company Announcement No. 13 of March 2, 2026
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, thi...
Wells Fargo Initiates Coverage on Genmab (GMAB) with Overweight Rating | GMAB Stock News
Wells Fargo Initiates Coverage on Genmab (GMAB) with Overweight Rating | GMAB Stock News
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; February 27, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 587,495 restricted stock units to members of manage...
Genmab to Participate in Upcoming Investor Conferences
Media Release COPENHAGEN, Denmark; February 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor c...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The incr...
Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Thurs...
Genmab AS (GMAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
Genmab AS (GMAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
Q4 2025 Genmab A/S Earnings Call Transcript
Q4 2025 Genmab A/S Earnings Call Transcript
Genmab Q4 2025 Earnings Report: Innovation Push Drives Profit Surge
Genmab A/S (Nasdaq: GMAB) released its full-year 2025 financial results, demonstrating the company’s improved operational execution. Total revenue reached $3.72... The post Genmab Q4 2025 Earnings Rep...
Genmab: Q4 Earnings Insights
Genmab (NASDAQ: GMAB) announced its Q4 earnings on Tuesday, February 17, 2026 at 11:00 AM. Here's a breakdown of the earnings report. Earnings Genmab missed estimated earnings by -88.64%, reporting a...
Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript
Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit program Completion expected no ...
Genmab Sees FY26 Revenue Of Up To $4.4 Bln
(RTTNews) - Genmab A/S (GMAB) published its 2025 annual report and projected higher revenue for 2026, supported by royalty growth and strong product sales.
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Media Release COPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) a nnounced today that it has filed its Annual Repor...
Genmab Publishes 2025 Annual Report
Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, ...
Genmab (GMAB) Receives Buy Rating from Jefferies with Positive Outlook
Genmab (GMAB) Receives Buy Rating from Jefferies with Positive Outlook